Medical News / Coverage ASRS 2019: Short-Term Effects of Ranibizumab Biosimilar Compared to Ranibizumab for DME

With fixed incomes a reality for many elderly patients, finding less expensive alternatives to current therapies is a hot topic for many retina specialists. Despite only being approved in India, the ranibizumab-biosimilar (Razumab) has caught the attention of many at the 2019 American Society of Retina Specialists Annual Meeting seeking an alternative treatment for patients with diabetic macular edema (DME). Source: MDmag By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization

read more

Findings of recent research demonstrate an intervention program, Balance after Baby, is promising for decreasing diabetes ... read more
A new analysis of data from the PIONEER program indicates reductions in HbA1c and body weight ... read more
Findings of a recent study suggest empagliflozin is associated with a decreased risk of hospitalization for ... read more
Testosterone treatment may prevent progression to or reverse type 2 diabetes in high-risk men who are ... read more